drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (autologous dendritic cell cancer vaccine)
drug_description
Autologous, ex vivo–prepared dendritic cells (1×10^7 cells) administered post–radical surgery to induce tumor-specific T-cell immunity (CD8+ cytotoxic and CD4+ helper responses) via antigen presentation and costimulation; intended to prevent recurrence/metastasis in survivin- or p53-positive solid tumors.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Dendritic Cells
drug_category
DC VACCINE
drug_class
Vaccine
drug_delivery_route
Unknown
drug_mechanism_of_action
Autologous ex vivo–prepared dendritic cells present tumor antigens (e.g., survivin/p53) via MHC I/II with costimulatory signals (CD80/CD86) to activate tumor-specific CD8+ cytotoxic and CD4+ helper T cells, enhancing Th1/CTL responses to eliminate residual disease and prevent recurrence/metastasis.
drug_name
Baize DC Injection / Super DC Vaccine (autologous dendritic cell vaccine)
nct_id_drug_ref
NCT06015269